Pfenex, the new spinout from Dow Chemical, has licenced its Pseudomonas fluorescens biomanufacturing technology to Merck for production of proteins for an undisclosed vaccine product. Pfenex will receive $52m in upfront and milestone payments and is entitled to royalty payments on any product sales derived from the agreement.
Xconomy
Tuesday 15 December 2009
Pfenex licenses technology to Merck
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment